Custom service
Serum-Free Expression System
Chemically defined culture, without the fetal bovine serum variable.
Serum in the culture medium is a convenience with a cost. It carries bovine immunoglobulins, transferrin, growth factors and an undefined mix of proteins that co-purify with the product, appear as contaminants in mass spectrometry and complicate every regulatory conversation. A serum-free, chemically defined medium removes all of it, and the purity gain shows up immediately in the purification yield.
Serum-free expression is not only a medium change. Cells adapted to suspension and serum-free conditions grow more slowly at first, and some clones lose productivity during the transition. The adaptation is done stepwise over four to six passages, with growth rate, viability and specific productivity measured at each step, and a research cell bank frozen once the line holds its titre in the new medium.
For antibodies produced in hybridomas, serum-free adaptation changes the downstream economics materially: protein A eluates contain far less bovine IgG, an ion exchange step is often unnecessary, and the product is defensible in a submission. For recombinant proteins in CHO or HEK, defined medium is simply the standard, and the question is only which formulation gives the best titre for the clone.
Serum-free expression is worth the adaptation time for any antibody or protein produced repeatedly over months, for anything heading toward a diagnostic or regulated use, and for mass spectrometry work where serum proteins swamp the product.
It is unnecessary for a single small research batch, and it is not a fix for a low-producing clone — adaptation preserves productivity but does not create it. Clone optimisation comes first.
Adaptation records include passage-by-passage growth rate, viability and productivity. The production lot is released with purity, concentration, bovine IgG content by ELISA, endotoxin and sterility where required, alongside the serum-grown reference for comparison.
Service Highlights
- Defined medium only. No serum, no hydrolysates of unknown composition, no animal-derived components anywhere in the train.
- Stepwise adaptation. Serum reduction over four to six passages, with growth and productivity measured at each step rather than guessed.
- Hybridoma and recombinant both. The same workflow applies to hybridoma lines and to CHO or HEK producers.
- Productivity preserved. Adaptation is stopped and the bank frozen only when titre matches or exceeds the serum condition.
- Downstream benefit quantified. Bovine IgG content of the purified product measured by ELISA before and after adaptation.
- Suspension-ready. Adapted lines grow in shaker flasks and bioreactors, which is the practical prerequisite for scale-up.
How the work runs
Line and medium assessment
Current growth conditions, productivity and medium options are reviewed, and a defined formulation is selected from commercial or in-house media.
Serum reduction
Serum stepped down in 5% increments every passage, with viability and growth rate recorded; a failing line stops here rather than losing the culture.
Productivity check
Specific antibody or protein production per cell measured against the serum condition, and the adaptation continued only where it holds.
Banking
A research cell bank frozen in defined medium with DMSO, with passage number and productivity recorded for each vial.
Expression run
Production culture in defined medium at the required scale, with metabolite and titre data collected.
Purification and comparison
Product purified and bovine IgG content, purity and yield compared with a serum-grown reference lot.
Specifications & timeline
- Cell lines
- Hybridoma, CHO, HEK293; other lines on evaluation
- Medium
- Chemically defined, protein-free or low-protein options
- Adaptation
- 4–6 passages of stepwise serum reduction
- Scale
- Flask to 20 L bioreactor
- Timeline
- 4–6 weeks including adaptation and production
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.